PL428798A1 - Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie - Google Patents
Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanieInfo
- Publication number
- PL428798A1 PL428798A1 PL428798A PL42879819A PL428798A1 PL 428798 A1 PL428798 A1 PL 428798A1 PL 428798 A PL428798 A PL 428798A PL 42879819 A PL42879819 A PL 42879819A PL 428798 A1 PL428798 A1 PL 428798A1
- Authority
- PL
- Poland
- Prior art keywords
- zinc gluconate
- preparation
- solid dosage
- weight
- dosage form
- Prior art date
Links
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 title abstract 3
- PBJNZCQJMWVIRT-MDQYBHOLSA-N inosine pranobex Chemical compound CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C2=NC=NC(O)=C2N=C1 PBJNZCQJMWVIRT-MDQYBHOLSA-N 0.000 title abstract 3
- 229960000476 inosine pranobex Drugs 0.000 title abstract 3
- 229960000306 zinc gluconate Drugs 0.000 title abstract 3
- 235000011478 zinc gluconate Nutrition 0.000 title abstract 3
- 239000011670 zinc gluconate Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000007909 solid dosage form Substances 0.000 title abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny oraz substancje wspomagające charakteryzująca się tym, że glukonian cynku jest w ilości od 3,11% do 4,51% masowych postaci, pranobeks inozyny w ilości 71,43% masowych postaci, karboksymetyloskrobii sodowej (typ A) w zakresie od 5% do 14% wagowych postaci oraz laurylosiarczanu sodu na poziomie od 0,7% do 1% wagowych postaci a zawartość mannitolu wynosi od 6% do 10,7% wagowych postaci oraz jej sposób otrzymywania oraz zastosowanie.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL428798A PL238168B1 (pl) | 2019-02-04 | 2019-02-04 | Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie |
| PCT/PL2020/050014 WO2020162773A1 (en) | 2019-02-04 | 2020-02-04 | A solid dosage form comprising zinc gluconate and inosine pranobex, a method for its preparation and its applications |
| EP20752394.5A EP3920892B1 (en) | 2019-02-04 | 2020-02-04 | A solid dosage form comprising zinc gluconate and inosine pranobex, a method for its preparation and its applications |
| AU2020218470A AU2020218470A1 (en) | 2019-02-04 | 2020-02-04 | A solid dosage form comprising zinc gluconate and inosine pranobex, a method for its preparation and its applications |
| US17/426,607 US20220202839A1 (en) | 2019-02-04 | 2020-02-04 | A solid dosage form comprising zinc gluconate and inosine pranobex, a method for its preparation and its applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL428798A PL238168B1 (pl) | 2019-02-04 | 2019-02-04 | Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL428798A1 true PL428798A1 (pl) | 2020-08-10 |
| PL238168B1 PL238168B1 (pl) | 2021-07-12 |
Family
ID=71943626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL428798A PL238168B1 (pl) | 2019-02-04 | 2019-02-04 | Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220202839A1 (pl) |
| EP (1) | EP3920892B1 (pl) |
| AU (1) | AU2020218470A1 (pl) |
| PL (1) | PL238168B1 (pl) |
| WO (1) | WO2020162773A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119606899A (zh) * | 2024-12-13 | 2025-03-14 | 重庆天致药业股份有限公司 | 一种肌苷片的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103120648B (zh) * | 2009-04-14 | 2015-02-11 | 北京赛而生物药业有限公司 | 一种异丙肌苷口服制剂及其制备方法 |
| JP2015063521A (ja) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | 高い薬物含有率を有する錠剤及びその製造方法 |
| PL239019B1 (pl) * | 2017-07-14 | 2021-10-25 | Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia | Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania |
-
2019
- 2019-02-04 PL PL428798A patent/PL238168B1/pl unknown
-
2020
- 2020-02-04 EP EP20752394.5A patent/EP3920892B1/en active Active
- 2020-02-04 US US17/426,607 patent/US20220202839A1/en not_active Abandoned
- 2020-02-04 WO PCT/PL2020/050014 patent/WO2020162773A1/en not_active Ceased
- 2020-02-04 AU AU2020218470A patent/AU2020218470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL238168B1 (pl) | 2021-07-12 |
| US20220202839A1 (en) | 2022-06-30 |
| AU2020218470A1 (en) | 2021-08-12 |
| EP3920892B1 (en) | 2023-11-15 |
| EP3920892A4 (en) | 2022-11-16 |
| WO2020162773A1 (en) | 2020-08-13 |
| EP3920892A1 (en) | 2021-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392313B (es) | Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina. | |
| BR0316532A (pt) | Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base | |
| MX2016007547A (es) | Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla. | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| MX386873B (es) | Composiciones farmacéuticas y usos de las mismas para tratar enfermedades cardiovasculares | |
| TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| GEP20227396B (en) | Compounds and their uses for alleviating menopause-associated symptoms | |
| EA200501008A1 (ru) | Вагинальная мукоадгезивная композиция, фармацевтический набор на ее основе, фармацевтическая дозированная форма для лечения вульвовагинального кандидоза и способ его лечения | |
| IL321873A (en) | Methods for altering body composition | |
| PL428798A1 (pl) | Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie | |
| MX2020008982A (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. | |
| MX2020001199A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| MY199648A (en) | Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof | |
| MX2018000078A (es) | Composiciones de limpieza y metodos para mejorar el desempeño de la fragancia. | |
| MX2019011005A (es) | Preparación que contiene al menos un fungicida quimico y una preparación que contiene cepas de aureobasidium pullulans. | |
| AR118985A1 (es) | Composición que comprende fibra y proteína | |
| EA202090827A1 (ru) | Пероральные композиции для лечения гастроэзофагеального рефлюкса | |
| PH12019501105B1 (en) | Oral care composition | |
| PH12019500115B1 (en) | Oral care composition | |
| MA54222A (fr) | Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées | |
| EA202190694A1 (ru) | Композиция поверхностно-активных веществ и ее применение | |
| AU2018218188A1 (en) | Lavatory cleansing block | |
| MX2021014425A (es) | Composicion para el cuidado bucal. | |
| BR112022001504A2 (pt) | Composto | |
| PL435611A1 (pl) | Mieszanina do fotodegradacji i sposób fotodegradacji |